ProKidney Posts $35.6M Q3 Loss as Trials Ramp

The Winston-Salem biopharmaceutical company reported a third-quarter loss of $35.6 million as spending on clinical studies grew.

Updated on Nov. 13, 2026 in Public Companies

Isometric editorial illustration of clear glass flasks and a kidney-shaped vessel on a bare steel lab bench, evoking costly clinical development.
ProKidney reported a third-quarter loss of $35.6 million, or 17 cents per share, as spending on Phase 3 clinical studies and manufacturing grew. AI Illustration. Upload story photo >

ProKidney Corp. reported a third-quarter loss of $35.6 million, or 17 cents per share, up from $16.5 million a year earlier. The company attributed higher costs to expanded clinical study and manufacturing activity as it advances its Phase 3 trials.

Why it matters

The loss reflects the cost of moving an experimental kidney therapy toward regulatory review, a stage that requires heavy spending before any revenue is possible. For Winston-Salem, ProKidney is the only mainstream publicly traded company based in the city, so its spending and growth carry weight for the local economy.

The company's third-quarter loss of $35.6 million came in narrower than the second-quarter loss of $46.4 million but roughly double the $16.5 million loss a year earlier. Analysts had expected a loss of 11 cents per share, compared with the reported 17 cents, and the filing does not say how long current cash will fund operations.

The players

ProKidney Corp.

ProKidney is a Winston-Salem biopharmaceutical company developing treatments for chronic kidney disease, and it is the only mainstream publicly traded company based in the city.

Edmund Ingham

Edmund Ingham is an equity analyst who estimated that rilparencel could generate up to $900 million in annual revenue if approved.

The details

ProKidney reported $174,000 in revenue for the quarter while operating expenses reached $53.7 million, driven by higher research and development costs tied to clinical studies and manufacturing. Professional fees rose with continued study enrollment, preparation for regulatory filings and additional staff, and the company now has more than 250 employees, up from 80 four years ago.

Timeline

  1. July 2025: The FDA agreed to an accelerated approval process for rilparencel.

  2. June 30: The company reported $141.9 million in cash, cash equivalents and marketable securities.

  3. Sept. 30: Study enrollment reached 320 patients.

  4. Third quarter 2026: The company reported its $35.6 million quarterly loss.

  5. First quarter 2027: ProKidney projects more than 500 study patients at full enrollment.

Market Landscape

The quarter's spending increase follows the FDA's July 2025 agreement to an accelerated approval process for rilparencel, which shifted the company toward a faster route to market. That pathway raises the stakes of the current trial ramp, since the company's cash position of $141.9 million must now cover enrollment that is projected to exceed 500 patients.

For residents of Winston-Salem, ProKidney's growth from 80 to more than 250 employees over four years represents local jobs tied to a single publicly traded employer. Shareholders face continued losses until the therapy reaches regulatory decisions, and no revenue from rilparencel is recorded yet.

The takeaway

Growth in a clinical-stage biotech is measured first in spending and enrollment rather than revenue, so the quarterly loss is best read alongside cash on hand and trial milestones. Readers tracking the company should watch the enrollment targets and cash position in upcoming filings.

What happens next

ProKidney projects reaching full enrollment of more than 500 study patients in the first quarter of 2027, and its full analysis results are targeted for the second half of 2029.

Further reading

For more on other publicly traded firms, explore Public Companies coverage.